Jump to navigation Jump to content

The place where great ideas thrive

Why invest in Edinburgh BioQuarter?

Partners are seeking private sector investment to ensure BioQuarter’s core knowledge and clinical base is complemented by a growing number of innovative companies. By working together, these enterprises will create new medical and biomedical products and services, delivering significant health, social and economic benefits for Scotland. This overall objective will be delivered through:

  • Development of specialist commercial infrastructure and service offering able to attract and grow a dynamic life sciences cluster
  • Creation of a commercially viable and investible development whereby the cluster becomes self sustaining
  • Development of a value proposition and brand able to compete with world-leading life sciences offerings
Watch Our Film

Development Opportunities

An opportunity for at least £300m of investment in property over the next five years.

There are a numerous opportunities to invest across Edinburgh BioQuarter. Partners have developed a robust financial model, a mini-masterplan which primarily focuses on the serviced development land adjacent to the existing Royal Infirmary of Edinburgh and Royal Hospital for Children and Young People. Planned development over the next five years includes clinical, academic and commercial space as well as a new city mortuary. Ancillary development is also required to include multi-story car parking, hotels, leisure and retail as well as a District Energy Network to complement the growing life sciences quarter.


£1.1bn

potential
investment
through the
east region
city deal


Invest in Our Companies

Scotland’s top life sciences companies at BioQuarter

We view the 25+ companies who choose to call BioQuarter home as very special and we want to support them to grow and succeed. We are proud that these multi award-winning life sciences companies and entrepreneurs have chosen to come here. We welcome and support investment into our tenant companies, and with two recent acquisitions in excess of £200m+ there are many opportunities amongst our growing cluster.

  • Roslin Cells based at BioQuarter has created over 80 new jobs and given rise to two further spin-off companies (Roslin CT and CENSO)
  • IoMET was a new start-up based at BioQuarter and was acquired by Merck for >£100s millions in 2016
  • Janssen Pharmaceuticals has invested over £6m to establish the Centre for Dementia Prevention at BioQuarter, with a commitment to recruit 100s of patients for dementia research
See the Companies at BioQuarter

14

new life science
companies raising £10m in
venture
funding
in the last
five years


Property and Commercial Agents

Edinburgh BioQuarter is working with consultant partners, Savills and CAM-SCI, in regards to property and commercial developments. For more information on property, viewings and development opportunities please contact our agents.


Commercialisation and Clinical Trials

Latest Case Studies

12.09.2018

Fios Genomics

Specialists in bioinformatics data analysis, Fios Genomics works with global pharmaceutical companies, contract research organisations and academic institutions from its BioQuarter base.

11.09.2018

Centre for Dementia Prevention

Based at BioQuarter since 2016, the University of Edinburgh’s Centre for Dementia Prevention is leading a major worldwide study into the condition.

05.09.2018

Proteus

Hugely innovative in shortening the distance from bench to bedside, the QMRI-based Proteus project’s work is revolutionising the ways lung diseases are diagnosed and managed.

05.09.2018

Centre for Cardiovascular Science

The Centre for Cardiovascular Science (CVS) is engaged in world-leading research into cardiovascular diseases. Co-located with the Royal Infirmary of Edinburgh and the University of Edinburgh’s Medical School, the CVS relies on collaboration to both drive discoveries and deliver new solutions.

05.09.2018

CALCIVIS

Founded in 2012 by CEO Adam Christie and CTO Bruce Vernon, CALCIVIS has recently overseen the UK launch of its revolutionary dental imaging technology.

05.09.2018

Aquila BioMedical

Beginning life as a University of Edinburgh start-up, Aquila BioMedical’s expertise in immunology, immuno-oncology and specialist histology supports a range of clients to discover their best route to clinic.

Contact
Us